Drugs / Sacubitril / Valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04753112 | Oct 2020 → Sep 2021 | pulmonary hypertension | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-07-07 | Novartis Pharmaceuticals | Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook novartis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril / Valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04753112 ↗ |
| Known as | Entresto | “Sacubitril / Valsartan Oral Tablet [Entresto]” NCT04753112 ↗ |
| Action | Inhibit | “angiotensin receptor-neprilysin inhibitor (ARNI)” NCT04753112 ↗ |
| Route | Oral | “Sacubitril / Valsartan Oral Tablet” NCT04753112 ↗ |